MADRID, June 24, 2017 /PRNewswire/ --
Ibrutinib: A promising new
treatment for chronic
graft versus host
disease.
Chronic graft versus host disease (cGVHD) is a serious and
life-threatening complication observed in most patients undergoing
allogeneic stem cell transplantations. Both B and T cells are known
to be involved in the pathophysiology of cGVHD. Ibrutinib, a
Bruton's tyrosine kinase inhibitor, is known to inhibit B cells;
recent studies have shown that ibrutinib also inhibits specific
subsets of T cells by blocking interleukin-2-inducible T-cell
kinase. In mouse models, ibrutinib delayed the progression and
reduced the severity of cGVHD. This multicenter, open-label trial
was conducted to evaluate the safety and efficacy of ibrutinib in
42 patients with active cGVHD whose disease had failed between 1
and 3 prior treatments; patients were given daily ibrutinib (420
mg) until cGVHD progression or dose limiting toxicity. At a median
follow-up of 13.9 months, the AE profile shows largely low-grade
events consistent with those reported for B cell malignancies
treated with ibrutinib and those observed in cGVHD patients on
corticosteroids. Serious AEs occurred in 22 patients (52%).
The overall cGVHD response rate was 67% with 71% of
responders showing a sustained response for ≥ 20 weeks. Patients
showed similar rates of response in all organ domains, and most
patients with multi-organ disease responded in multiple organs.
Corticosteroid doses were also reduced in most responders, and 5
responders discontinued corticosteroids completely. The clinical
benefit make ibrutinib a promising treatment option for patients
with cGVHD whose disease failed to respond to frontline
therapy.
(Logo:
http://mma.prnewswire.com/media/524821/EHA_Logo.jpg )
Presenter:Dr Iskra
Pusic
Affiliation: Washington
University School of Medicine, St.
Louis, MO, USA
Topic: IBRUTINIB FOR CHRONIC GRAFT-VERSUS-HOST DISEASE
AFTER FAILURE OF FRONTLINE CORTICOSTEROIDS: RESULTS OF A
MULTICENTER OPEN-LABEL PHASE 2 STUDY
Abstract S441 will be presented by Iskra
Pusic on Saturday, June 24,
16:00 - 17:15 in Room N103.
About the EHA Annual Congress
Hematology is a specialty that covers everything to do with blood:
its origin in the bone marrow, diseases of blood and their
treatments. The latest data on research and developments will be
presented. The topics range from stem cell physiology and
development, to leukemia, lymphoma, myeloma - diagnosis and
treatment; red blood cells -, white blood cells- and platelet
disorders; thrombosis and bleeding disorders.
SOURCE European Hematology Association